Search clinical trials for: Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors

Total 4739 results

H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Recruiting

SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

Cervical Cancer | Cervical Cancer Recurrent | Cervical Cancer Metastatic

United States
University College, London
Merck Sharp & Dohme LLC

Active, not recruiting

A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) (PORT)

Cutaneous T Cell Lymphoma | Mycosis Fungoides/Sezary Syndrome

United Kingdom
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Completed

Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

Small Cell Lung Cancer | Extensive-stage Small Cell Lung Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute

Terminated

Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

United States
Abramson Cancer Center at Penn Medicine

Recruiting

BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy (BreastVAX)

Breast Cancer

United States
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC

Recruiting

A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy

Metastatic Pancreatic Ductal Adenocarcinoma | Homologous Recombination Deficiency (HRD)

United States
ImmuneSensor Therapeutics Inc.

Recruiting

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

Oligoprogressive

United States
M.D. Anderson Cancer Center

Recruiting

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

Metastatic Malignancy

United States
Fujian Cancer Hospital
Zhangzhou Municipal Hospital of Fujian Province

Recruiting

Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer

Cervical Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital of Jinan University; Shenzhen University General...

Recruiting

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Carcinoma | Digestive System Neoplasms | Intrahepatic Cholangiocarcinoma | First-line Treatment | PD-1 Inhibitor

China
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States, Italy, Japan, Spain, Taiwan, Korea, Republic of, France, Poland, Russian Federation, Turkey
Asan Medical Center

Recruiting

A Prospective Cohort Study of Patients With Hepatobiliary Cancer Treated With Immune Checkpoint Inhibitors

Hepatocellular Carcinoma | Biliary Tract Cancer

Korea, Republic of
Hoffmann-La Roche

Recruiting

A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator)

Solid Tumors

Spain
Oslo University Hospital

Active, not recruiting

A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. (Ipi4)

Malignant Melanoma

Norway
Bristol-Myers Squibb

Completed

A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors

Advanced Cancer

China
Beijing Friendship Hospital

Recruiting

Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer

Locally Advanced Rectal Cancer

China
University Health Network, Toronto
Pfizer

Recruiting

Talazoparib and Thoracic RT for ES-SCLC

Lung Cancer | Small-Cell Lung Cancer

Canada
Sidney Kimmel Cancer Center at Thomas Jefferson...
Merck Sharp & Dohme LLC

Completed

Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer

Head and Neck Squamous Cell Carcinoma | Metastatic Renal Cell Cancer | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Renal Cell Carcinoma | Recurrent Skin Carcinoma | Stage III Renal Cell Cancer | Stage IV Lung Cancer | Stage IV Skin Melanoma

United States
Navire Pharma Inc., a BridgeBio company
Bristol-Myers Squibb

Recruiting

SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

Solid Tumor | Non Small Cell Lung Cancer

United States
Shanghai Zhongshan Hospital

Unknown

Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer (OASIS)

Gastric Adenocarcinoma | Esophageal Squamous Cell Carcinoma
Omega Therapeutics

Recruiting

A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene (MYCHELANGELO I)

Hepatocellular Carcinoma | Solid Tumor | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Recurrent | Liver, Cancer of, Non-Resectable

United States, Hong Kong, Korea, Republic of, Singapore, Taiwan
Grit Biotechnology

Not yet recruiting

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Squamous Cell Carcinoma

HNSCC | Adults

China
1ST Biotherapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

Advanced Solid Tumor

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection

Hepatocellular Carcinoma | Graft Rejection | Immunotherapy | Immune Checkpoint Inhibitor

China
Nanfang Hospital of Southern Medical University
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

Iguratimod Combined With Tofacitinib in the Treatment of Rheumatoid Arthritis

Rheumatoid Arthritis
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC

Advanced Hepatocellular Carcinoma (HCC)

Italy, Poland, Singapore, United States, China, Ukraine
Compugen Ltd
Bristol-Myers Squibb

Active, not recruiting

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

Breast Cancer | Ovarian Cancer | Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Advanced Cancer | Colo-rectal Cancer | Ovarian Neoplasm | Neoplasm Malignant | Lung Neoplasm

United States
Changzhou Cancer Hospital of Soochow University

Completed

An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer (EASE)

Non-small Cell Lung Cancer

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
UNICANCER

Not yet recruiting

Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery (CAPPA)

Triple Negative Breast Neoplasms
Dan Zandberg
Merck Sharp & Dohme LLC; ISA Pharmaceuticals

Recruiting

HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma | HPV-Related Squamous Cell Carcinoma

United States
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade Glioma (NIVOGLIO)

High Grade Glioma

France
Jacobio Pharmaceuticals Co., Ltd.
AbbVie

Recruiting

JAB-3068 Activity in Adult Patients With Advanced Solid Tumors

Non Small Cell Lung Cancer | Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...
The First Affiliated Hospital with Nanjing Medical University; Fujian Cancer... and other collaborators

Recruiting

PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer

Esophageal Neoplasms

China
Second Affiliated Hospital of Soochow University

Not yet recruiting

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

Carcinoma, Non-Small-Cell Lung | Carcinoma Breast

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure Infections

Skin Infection

China
Shanghai Chest Hospital

Not yet recruiting

Salvage Immunotherapy and Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant Chemoradiotherapy (SINCERE)

Esophageal Squamous Cell Carcinomas
University of Wisconsin, Madison
Merck Sharp & Dohme LLC

Completed

PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer

Colorectal Cancer | Colorectal Adenocarcinoma | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Metastatic Carcinoma in the Liver

United States
Idera Pharmaceuticals, Inc.
Bristol-Myers Squibb

Terminated

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Metastatic Melanoma

United States, Canada, Spain, United Kingdom, France, Australia, Germany, Italy, Netherlands, Sweden, Czechia
China Medical University Hospital

Unknown

Study of Combined Sorafenib With Radiotherapy in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

Taiwan
Fujian Medical University

Active, not recruiting

The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer

Locally Advanced Gastric Cancer

China
Beijing Friendship Hospital
Peking University First Hospital; Peking University People's Hospital; Peking... and other collaborators

Recruiting

Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer (POLAR-STAR)

Locally Advanced Rectal Cancer

China
Second Affiliated Hospital, School of Medicine,...
Zhejiang Cancer Hospital; Sun Yat-sen University; Ningbo Medical Center Lihuili... and other collaborators

Recruiting

Multi-center Observational Study on the Progression of Atherosclerotic Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up

Plaque, Atherosclerotic | Programmed Cell Death Protein 1 Inhibitor

China
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

Head and Neck Neoplasms

United States, Australia, Austria, Belgium, Brazil, Canada, Colombia, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Spain, Taiwan, Turkey, United Kingdom
Fudan University

Recruiting

Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma

Gastric Cancer

China
Asan Medical Center

Not yet recruiting

FMT With Nivolumab in Patients With Advanced Solid Cancers Who Have Progressed During Anti-PD-(L)1 Therapy

Solid Carcinoma
Lytix Biopharma AS
Laboratory Corporation of America; OWL

Active, not recruiting

Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma (ATLAS-IT-05)

Advanced Melanoma

United States, Spain, France, Norway
Taipei Medical University WanFang Hospital

Completed

Immune Profile and Prognosis of Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy (RFA)

Liver Cancer

Taiwan
Shanghai Chest Hospital

Recruiting

Analysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

China
Case Comprehensive Cancer Center

Active, not recruiting

Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM

Glioblastoma

United States

Search clinical trials for: Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations